Description

Lindqvist et al identified risk factors associated with venous thromboembolism (VTE) in women during the postpartum period. Appropriate management depends on the level of risk. The authors are from Malmo University, Lund University and Karolinska Hospital in Sweden.


Condition

Modifier

Risk Level

Factor V Leiden

heterozygous

1

Factor V Leiden

homozygous

3

prothrombin gene mutation

heterozygous

1

prothrombin gene mutation

homozygous

3

overweight in early pregnancy

BMI > 28 k per sq m

1

cesarean section

 

1

family history of thrombosis in a first degree relative < 60 years of age

 

1

age > 40

 

1

pre-eclampsia

 

1

abruptio placenta

 

1

protein S deficiency

 

2

protein C deficiency

 

2

immobilization

>= 1 week

2

lupus anticoagulant

 

2

cardiolipin antibodies

 

2

history of previous venous thrombo-embolic event (VTE)

 

4

history of repeated VTE

 

5

antiphospholipid syndrome (APS)

without prior VTE

4

antiphospholipid syndrome (APS)

with prior VTE

5

mechanical heart valve

 

5

need for continuous warfarin prophylaxis

 

5

antithrombin deficiency

 

5

other risk factor

 

1

 

 

Risk Level

Risk Relative to Pregnancy

Management

0

none

none

1

5-fold increase

none

2

25 fold increase

short term (7 days) low molecular weight heparin after delivery or if immobilized

3

125 fold increase

6 week low molecular weight heparin starting within 4 hours after delivery

4

high (10% absolute)

antepartum prophylaxis AND continuing >= 6 weeks of low molecular weight heparin after delivery

5

very high (> 15% absolute)

high dose antepartum prophylaxis AND >= 12 weeks of low molecular weight heparin after delivery

 

Additional recommendations:

(1) A woman with antiphospholipid syndrome, lupus anticoagulant, or anticardiolipin antibody should receive ASA 75 mg/d (low dose).

(2) Factor-Xa monitoring should be performed for very high risk patients.

(3) Antepartum therapy for high risk patients is started during the second trimester.

(4) Antepartum therapy for very high risk patients is started as soon as possible, sometimes preceding the pregnancy.


 


To read more or access our algorithms and calculators, please log in or register.